Genomic Health, Inc.

Rush-presbyterian-st. Luke's Medical Center

Rush University Medical Center

Aventisub II Inc.

Nsabp Foundation, Inc.

Aventis Corporation Gmbh

Steve Shak

Audrey Goddard

Joffre B Baker

Maureen T Cronin

Michael C Kiefer

Soonmyung Paik

Michael Graham Walker

Wayne Cowens

Tara Maddala

John L Bryant

Melody A Cobleigh

Dejan Knezevic

Michael R Crager

Frederick L Baehner

Mark Lee

William F Novotny

Diana Cherbavaz

Carl L Millward

Robert J Pelham

Jose Baselga

William Novotny

Carl Yoshizawa

Robert Pelham

Robert Gray

The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. The invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies.

Gene expression profiling in biopsied tumor tissues

The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.

Gene expression markers for breast cancer prognosis

The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.

Gene expression profile algorithm and test for determining prognosis of prostate cancer

The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.

Gene expression profiling of EGFR positive cancer

The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. Th invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies.

Growing community of inventors

Hillsborough, CA, United States of America

Steve Shak